MÚLTIPLOS EPISÓDIOS DE INFARTO AGUDO DO MIOCÁRDIO APÓS USO DE ANTICOAGULANTE - RELATO DE CASO

Authors

  • Gustavo Moreira Clivatti Acadêmico de medicina, Universidade Federal do Paraná - UFPR. http://orcid.org/0000-0001-7112-2847
  • João Pedro Pereira da Cunha Médico residente, Hospital de Clínicas, Universidade Federal do Paraná - UFPR.
  • Gustavo Lenci Marques Professor, Hospital de Clínicas, Universidade Federal do Paraná - UFPR.
  • Caio Cesar Cervi Lagana Médico residente, Hospital de Clínicas, Universidade Federal do Paraná - UFPR.
  • Luciana de Cerjat Bernardes Pereira da Cunha Médica, Hospital de Clínicas, Universidade Federal do Paraná - UFPR.
  • Gibran Avelino Frandoloso Médico, Hospital de Clínicas, Universidade Federal do Paraná - UFPR.

DOI:

https://doi.org/10.5380/rmu.v3i3.48266

Keywords:

heparina, infarto do miocárdio, trombocitopenia.

Abstract

Objetivo: Descrever um caso de paciente com trombocitopenia induzida por heparina (TIH) tipo II, que se manifestou através de consecutivos quadros de infartos agudos do miocárdio. Relato de Caso: Trata-se de uma paciente do sexo feminino, 70 anos, admitida no HC-UFPR por quadro de infarto agudo do miocárdio (IAM), duas semanas após internamento hospitalar por pneumonia e insuficiência cardíaca descompensada, manejadas com antibioticoterapia, heparina e diuréticos. Evoluiu com quadro de plaquetopenia a esclarecer e dois episódios subsequentes de IAM. Após a retirada da heparina, evoluiu com estabilização clínica - aumento do número de plaquetas, sem novos eventos trombótico e regularização dos testes laboratoriais. Recebeu alta hospitalar e, no retorno ambulatorial, apresentou anticorpos anti-plaqueta positivos e uma revisão de prontuário com história de múltiplas exposições a heparinas não fracionada e de baixo peso molecular. Conclusão: Diante do grande número de pacientes expostos à heparina, seus principais efeitos colaterais, dentre os quais a TIH, precisam ser conhecidos. Deve-se atentar para a possibilidade de a heparina possuir associação causal com IAM, quando associado à trombocitopenia, visto que a tendência nessas situações é de se manter a medicação a fim de evitar quadros trombóticos futuros.

References

Warkentin TE. Heparin-Induced Thrombocytopenia: Diagnosis and Management. Circulation. 2004; 110:e454-e458.

Brieger DB, Mak KH, Kottke-Marchant K, et al. Heparin-Induced Thrombocytopenia. J Am Coll Cardiol. 1998; 31(7):1449-1459.

Warkentin TE, Aird WC, Rand JH. Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid sydrome. Hematology (Am Soc Hematol Educ Program). 2003; 497-519.

Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332(2):1330-1335.

Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol. 2003; 121(4)535-555.

Selleng K, Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Crit Care Med. 2007; 35(4):1165-1176.

Greinacher A, Farner B, Kroll H, et al. Clinical features of heparin-induced thrombocytopenia including risk factor for thrombosis. A retrospective analysis of 408 patients. Thromb Haemost. 2005; 94(1):132-5.

Mak KH, Kottke-Marchant K, Brooks LM, Topol EJ. In vitro efficacy of platelet glycoprotein IIb/IIIa antagonist in blocking platelet function in plasma of patients with heparin-induced thrombocytopenia. Thromb Haemost. 1998; 80(6):989-993.

Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparin-induced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003; 101(8):2955-2959.

Cines DB, Rauova L, Arepally G, et al. Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. J Clin Apher. 2007; 22(1):31-36.

Kelton JG. Heparin-induced thrombocytopenia: an overview. Blood Rev. 2002; 16(1):77-80.

Rice L, Attisha WK, Drexler A, Francis JL. Delayed-onset heparin-induced thrombocytopenia. Ann Intern Med. 2002; 136(3):210-215.

Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr Hematol Rep. 2003; 2:148-157.

Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4 T’s) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost. 2006; 4:759-765.

Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986; 67(1):27-30.

Downloads

Published

2016-11-29

How to Cite

Clivatti, G. M., da Cunha, J. P. P., Marques, G. L., Lagana, C. C. C., da Cunha, L. de C. B. P., & Frandoloso, G. A. (2016). MÚLTIPLOS EPISÓDIOS DE INFARTO AGUDO DO MIOCÁRDIO APÓS USO DE ANTICOAGULANTE - RELATO DE CASO. Revista Médica Da UFPR, 3(3). https://doi.org/10.5380/rmu.v3i3.48266

Issue

Vol. 3 No. 3 (2016)

Section

Relatos de Caso

License

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).